New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA

References

• RoosenAChappleCRDmochowskiRRA refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literatureEur Urol200956581081919683859
   PubMed Web of Science ®Google Scholar
• KanaiAAnderssonKEBladder afferent signaling: recent findingsJ Urol201018341288129520171668
   PubMed Web of Science ®Google Scholar
• AnderssonKELUTS treatment: future treatment optionsNeurourol Urodyn200726Suppl 693494717696154
   PubMed Web of Science ®Google Scholar
• CerrutoMAAsimakopoulosADArtibaniWInsight into new potential targets for the treatment of overactive bladder and detrusor overactivityUrol Int20128911822738896
   PubMed Web of Science ®Google Scholar
• HoodBAnderssonKECommon theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderInt J Urol2013201212723072271
   PubMed Web of Science ®Google Scholar
• AnderssonKEAntimuscarinic mechanisms and the overactive detrusor: an updateEur Urol201159337738621168951
   PubMed Web of Science ®Google Scholar
• GormleyEALightnerDJBurgioKLDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association; Society of Urodynamics, Female Pelvic Medicine and Urogenital ReconstructionJ Urol2012188Suppl 62455246323098785
   PubMed Web of Science ®Google Scholar
• LucasMGBoschRJBurkhardFCEAU guidelines on assessment and nonsurgical management of urinary incontinenceEur Urol20126261130114222985745
   PubMed Web of Science ®Google Scholar
• AbramsPAnderssonKEMuscarinic receptor antagonists for overactive bladderBJU Int20071005987100617922784
   PubMed Web of Science ®Google Scholar
• ChappleCRKhullarVGabrielZMustonDBitounCEWeinsteinDThe effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysisEur Urol200854354356218599186
   PubMed Web of Science ®Google Scholar
• AnderssonKEChappleCRCardozoLPharmacological treatment of overactive bladder: report from the International Consultation on IncontinenceCurr Opin Urol200919438039419448545
   PubMed Web of Science ®Google Scholar
• AnderssonKEMuscarinic acetylcholine receptors in the urinary tractHandb Exp Pharmacol201120231934421290234
   PubMedGoogle Scholar
• IggoATension receptors in the stomach and the urinary bladderJ Physiol1955128359360713243351
   PubMed Web of Science ®Google Scholar
• HerbisonPHay-SmithJEllisGMooreKEffectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic reviewBMJ2003326739484184412702614
   PubMed Web of Science ®Google Scholar
• NovaraGGalfanoASeccoSSystematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladderEur Urol200854474076318632201
   PubMed Web of Science ®Google Scholar
• BasraRKWaggAChappleCA review of adherence to drug therapy in patients with overactive bladderBJU Int2008102777477918616691
   PubMed Web of Science ®Google Scholar
• SearsCLLewisCNoelKAlbrightTSFischerJROveractive bladder medication adherence when medication is free to patientsJ Urol201018331077108120092838
   PubMed Web of Science ®Google Scholar
• WaggACompionGFaheyASiddiquiEPersistence with prescribed antimuscarinic therapy for overactive bladder: a UK experienceBJU Int2012110111767177422409769
   PubMed Web of Science ®Google Scholar
• GomesTJuurlinkDNMamdaniMMComparative adherence to oxybutynin or tolterodine among older patientsEur J Clin Pharmacol2012681979921710237
   PubMed Web of Science ®Google Scholar
• LeeYSChooMSLeeJYOhSJLeeKSSymptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trialInt J Clin Pract2011659997100421849011
   PubMed Web of Science ®Google Scholar
• MadhuvrataPCodyJDEllisGHerbisonGPHay-SmithEJWhich anticholinergic drug for overactive bladder symptoms in adultsCochrane Database Syst Rev20121CD00542922258963
   PubMed Web of Science ®Google Scholar
• KesslerTMBachmannLMMinderCAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachPLoS One201162e1671821373193
   PubMed Web of Science ®Google Scholar
• AnderssonKEOlshanskyBTreating patients with overactive bladder syndrome with antimuscarinics: heart rate considerationsBJU Int200710051007101417922785
   PubMed Web of Science ®Google Scholar
• AnderssonKECampeauLOlshanskyBCardiac effects of muscarinic receptor antagonists used for voiding dysfunctionBr J Clin Pharmacol201172218619621595741
   PubMed Web of Science ®Google Scholar
• IgawaYMichelMCPharmacological profile of β(3)-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndromeNaunyn Schmiedebergs Arch Pharmacol2013386317718323263450
   PubMed Web of Science ®Google Scholar
• KanieSOtsukaAYoshikawaSPharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor stripsUrology2012793744. e1e722197203
   PubMed Web of Science ®Google Scholar
• OhlsteinEHvon KeitzAMichelMCA multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladderEur Urol201262583484022695239
   PubMed Web of Science ®Google Scholar
• EltinkCLeeJSchaddeleeMSingle dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladderInt J Clin Pharmacol Ther2012501183885022943933
   PubMed Web of Science ®Google Scholar
• KrauwinkelWvan DijkJSchaddeleeMPharmacokinetic properties of mirabegron, a β(3)-adrenoceptor agonist: results from two Phase I, randomized, multiple-dose studies in healthy young and elderly men and womenClin Ther201234102144216023063375
   PubMed Web of Science ®Google Scholar
• TakusagawaSvan LierJJSuzukiKAbsorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteersDrug Metab Dispos201240481582422269146
   PubMed Web of Science ®Google Scholar
• TakusagawaSYajimaKMiyashitaAUeharaSIwatsuboTUsuiTIdentification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonistXenobiotica2012421095796722509825
   PubMed Web of Science ®Google Scholar
• TakusagawaSMiyashitaAIwatsuboTUsuiTIn vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonistXenobiotica201242121187119622834478
   PubMed Web of Science ®Google Scholar
• BiersSMReynardJMBradingAFThe effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladderBJU Int20069861310131417026593
   PubMed Web of Science ®Google Scholar
• TakasuTUkaiMSatoSEffect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder functionJ Pharmacol Exp Ther2007321264264717293563
   PubMed Web of Science ®Google Scholar
• SvaløJNordlingJBoucheloucheKAnderssonKEKorstanjeCBouchelouchePThe novel β(3)-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivityEur J Pharmacol20126991–310110523246623
   PubMed Web of Science ®Google Scholar
• HatanakaTUkaiMWatanabeMIn vitro and in vivo pharmacological profile of the selective β(3)-adrenoceptor agonist mirabegron in ratsNaunyn Schmiedebergs Arch Pharmacol2013386324725323239087
   PubMed Web of Science ®Google Scholar
• HatanakaTUkaiMWatanabeMEffect of mirabegron, a novel β(3)-adrenoceptor agonist, on bladder function during storage phase in ratsNaunyn Schmiedebergs Arch Pharmacol20133861717823224420
   PubMed Web of Science ®Google Scholar
• GillespieJIPaleaSGuilloteauVGuerardMLluelPKorstanjeCModulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstructionBJU Int20121102 Pt 2E132E14222734512
   PubMed Web of Science ®Google Scholar
• AizawaNIgawaYNishizawaOWyndaeleJJEffects of CL316,243, a β3 adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the ratNeurourol Urodyn201029577177619816919
   PubMed Web of Science ®Google Scholar
• AizawaNHommaYIgawaYEffects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutyninEur Urol20126261165117322981677
   PubMed Web of Science ®Google Scholar
• ChappleCRYamaguchiORidderAClinical proof of concept study (Blossom) shows novel β3adrenoreceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladderEur Urol Suppl20087329239Abstr674
   Web of Science ®Google Scholar
• ChappleCWyndaeleJJvan KerrebroeckPRadziszewskiPDvorakVDose ranging study of once-daily mirabegron (YM178), a novel selective β3adrenoreceptor agonist, in patients with overactive bladder (OAB)Eur Urol Suppl201092249Abstr774
   Web of Science ®Google Scholar
• NittiVWAuerbachSMartinNCalhounALeeMHerschornSResults of a randomized Phase III trial of mirabegron in patients with overactive bladderJ Urol2012S00225347120521605210
   Google Scholar
• KhullarVAmarencoGAnguloJCEfficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trialEur Urol201363228329523182126
   PubMed Web of Science ®Google Scholar
• Van KerrebroeckPBarkin2Castro-DiazDRandomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB)Presented at the 42nd Annual Meeting of the International Continence SocietyBeijing, ChinaOctober 15–19, 2012
   Google Scholar
• NittiVRosenbergSMitchesonHDRandomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outletJ Urol2012187Suppl 4e756
   Web of Science ®Google Scholar
• ChappleCRKaplanSAMitchesonDRandomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladderEur Urol201363229630523195283
   PubMed Web of Science ®Google Scholar
• Mirabegron prescribing information Available from: http://www.us.astellas.com/docs/myrbetriq-full-pi.pdfAccessed February 26, 2013
   Google Scholar
• MalikMvan GelderenEMLeeJHProarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT studyClin Pharmacol Ther201292669670623149929
   PubMed Web of Science ®Google Scholar
• HumeauYDoussauFGrantNJPoulainBHow botulinum and tetanus neurotoxins block neurotransmitter releaseBiochimie200082542744610865130
   PubMed Web of Science ®Google Scholar
• ChancellorMBFowlerCJApostolidisADrug insight: biological effects of botulinum toxin A in the lower urinary tractNat Clin Pract Urol20085631932818461049
   PubMedGoogle Scholar
• CoelhoACruzFCruzCDAvelinoASpread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin actionEur Urol20126161178118422306320
   PubMed Web of Science ®Google Scholar
• AokiKRReview of a proposed mechanism for the antinociceptive action of botulinum toxin type ANeurotoxicology200526578579316002144
   PubMed Web of Science ®Google Scholar
• RappDETurkKWBalesGTCookSPBotulinum toxin type A inhibits calcitonin gen-related peptide release from isolated rat bladderJ Urol20061753 Pt 11138114216469640
   PubMed Web of Science ®Google Scholar
• MengJWangJLawrenceGDollyJOSynaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potentialJ Cell Sci2007120Pt 162864287417666428
   PubMed Web of Science ®Google Scholar
• LucioniABalesGTLotanTLMcGeheeDSCookSPRappDEBotulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammationBJU Int2008101336637018184328
   PubMed Web of Science ®Google Scholar
• IkedaYZabbarovaIBirderLBotulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladderEur Urol20126261157116422480459
   PubMed Web of Science ®Google Scholar
• KheraMSomogyiGTKissSBooneTBSmithCPBotulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injuryNeurochem Int200445798799315337297
   PubMed Web of Science ®Google Scholar
• SmithCPGangianoDAMunozABotulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injuryNeurochem Int20085261068107518187233
   PubMed Web of Science ®Google Scholar
• TakahashiRYunokiTNaitoSYoshimuraNDifferential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in ratsJ Urol201218851993199922999538
   PubMed Web of Science ®Google Scholar
• ApostolidisAPoptaRYiangouYDecreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivityJ Urol2005174397798216094018
   PubMed Web of Science ®Google Scholar
• DattaSNRoosenAOullenAImmunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administrationJ Urol201018462578258521030043
   PubMed Web of Science ®Google Scholar
• SahaiAKhanMSDasguptaPEfficacy of botulinum toxin A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trialJ Urol200717762231223617509328
   PubMed Web of Science ®Google Scholar
• DmochowskiRChappleCNittiVWEfficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialJ Urol201018462416242220952013
   PubMed Web of Science ®Google Scholar
• MangeraAAnderssonKEApostolidisAContemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)Eur Urol201160478479521782318
   PubMed Web of Science ®Google Scholar
• TincelloDGKenyonSAbramsKRBotulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomized blinded placebo-controlled trial of 240 women (the RELAX study)Eur Urol201262350751422236796
   PubMed Web of Science ®Google Scholar
• NittiVWDmochowskiRHerschornSEMBARK Study GroupOnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a Phase 3 randomized placebo-controlled trialJ Urol2012 pii:S0022-5347(12)05849-1
   Google Scholar
• RovnerEKennellyMSchulte-BauklohHZhouJHaag-MolkentellerCDasguptaPUrodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladderNeurourol Urodyn201130455656221351127
   PubMed Web of Science ®Google Scholar
• KanagarajahPAyyathuraiRCarusoDJGomezCGousseAERole of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivityInt Urol Nephrol2012441919721643644
   PubMed Web of Science ®Google Scholar
• BrubakerLRichterHEViscoARefractory idiopathic urge urinary incontinence and botulinum A injectionJ Urol2008180121722218499184
   PubMed Web of Science ®Google Scholar